S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
NYSEAMERICAN:IBIO

iBio - IBIO Stock Forecast, Price & News

$1.37
+0.45 (+48.91%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.88
$1.49
50-Day Range
N/A
52-Week Range
$0.36
$16.51
Volume
8.30 million shs
Average Volume
1.25 million shs
Market Capitalization
$12.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.50

iBio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
2,637.2% Upside
$37.50 Price Target
Short Interest
Bearish
15.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.57 out of 5 stars

IBIO stock logo

About iBio (NYSEAMERICAN:IBIO) Stock

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.

Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

IBIO Stock News Headlines

The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
iBio Inc. stock falls Thursday, underperforms market
iBio Inc. stock falls Thursday, underperforms market
iBio Announces Proposed Underwritten Public Offering
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
iBio Announces CEO Departure
iBio Accelerates Transformation to AI-Powered Biotech
iBio, Inc. (IBIO)
3 Healthcare Stocks to Sell Before They Die - InvestorPlace
Ibio earnings, Revenue miss in Q1 - Investing.com India
iBio reports FY results (NYSE:IBIO) - Seeking Alpha
See More Headlines
Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

IBIO Company Calendar

Last Earnings
11/15/2021
Today
2/08/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:IBIO
Previous Symbol
NASDAQ:IBIO
Employees
49
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.50
High Stock Price Forecast
$37.50
Low Stock Price Forecast
$37.50
Forecasted Upside/Downside
+2,637.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-50,300,000.00
Net Margins
-2,004.10%
Pretax Margin
-2,290.21%

Debt

Sales & Book Value

Annual Sales
$2.38 million
Book Value
$7.27 per share

Miscellaneous

Free Float
8,793,000
Market Cap
$12.34 million
Optionable
Not Optionable
Beta
-3.15

Key Executives

  • Martin B. Brenner
    Chief Executive & Scientific Officer
  • Mike Jenkins
    Vice President-Operations
  • Robert M. Lutz
    Chief Financial & Business Officer
  • Phan Dillon
    Vice President, Head-Research & Development
  • Matthew Luter
    Vice President-Information Technology













IBIO Stock - Frequently Asked Questions

Should I buy or sell iBio stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IBIO shares.
View IBIO analyst ratings
or view top-rated stocks.

What is iBio's stock price forecast for 2023?

2 analysts have issued 1 year target prices for iBio's stock. Their IBIO share price forecasts range from $37.50 to $37.50. On average, they anticipate the company's stock price to reach $37.50 in the next twelve months. This suggests a possible upside of 2,637.2% from the stock's current price.
View analysts price targets for IBIO
or view top-rated stocks among Wall Street analysts.

Are investors shorting iBio?

iBio saw a increase in short interest in December. As of December 30th, there was short interest totaling 1,080,000 shares, an increase of 18.2% from the December 15th total of 913,500 shares. Based on an average trading volume of 445,400 shares, the days-to-cover ratio is presently 2.4 days. Approximately 10.5% of the shares of the stock are sold short.
View iBio's Short Interest
.

How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) announced its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.25) by $0.25. The biotechnology company had revenue of $0.21 million for the quarter. iBio had a negative trailing twelve-month return on equity of 74.73% and a negative net margin of 2,004.10%.

When did iBio's stock split?

Shares of iBio reverse split before market open on Tuesday, October 11th 2022. The 1-25 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia Oyj (NOK) and Moderna (MRNA).

What is iBio's stock symbol?

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

Who are iBio's major shareholders?

iBio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Eastern Capital Ltd, James P Mullaney, Robert L Erwin and Robert Matthew Lutz.
View institutional ownership trends
.

How do I buy shares of iBio?

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iBio's stock price today?

One share of IBIO stock can currently be purchased for approximately $1.37.

How much money does iBio make?

iBio (NYSEAMERICAN:IBIO) has a market capitalization of $12.34 million and generates $2.38 million in revenue each year. The biotechnology company earns $-50,300,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis.

How can I contact iBio?

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The official website for the company is www.ibioinc.com. The biotechnology company can be reached via phone at (979) 446-0027, via email at ir@ibioinc.com, or via fax at 302-356-1173.

This page (NYSEAMERICAN:IBIO) was last updated on 2/8/2023 by MarketBeat.com Staff